Cart
sales@molnova.com
FGFR
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a receptor tyrosine kinase (RTK) signaling pathway that fundamentally regulates embryogenesis, angiogenesis, tissue homeostasis, and wound repair. The FGF family contains 22 known ligands and FGFs interact with the extracellular matrix as well as the cell surface via stabilization by heparan sulphate proteoglycans (HSPGs). The communications of FGFs with HSPGs has been shown to be essential for FGF signal transduction. The FGFR receptors (1-4) can become activated by mutation, translocation, or gene amplification. An increase in circulating FGF ligands can also cause activation. Downstream signaling can trigger the mitogen activated protein kinase (MAPK) pathway, the phosphoinositide-3-kinase (PI3K/Akt) pathway, the phosphorylation of the signal transducer and activator of transcription (STAT), and the PLCγ activation of the DAG-PKC and IP3-Ca2+ cascade resulting in DNA transcription. Negative feedback loops can attenuate the signaling cascade at varying levels. The FGFR signaling pathway represents a major target for cancer therapeutics as it plays a crucial role in tumor proliferation, angiogenesis, migration, and survival.
References
1.Chae YK, et al. Oncotarget. 2017;8(9):16052–16074.
References
1.Chae YK, et al. Oncotarget. 2017;8(9):16052–16074.
Angiogenesis
FGFR
-
Recifercept
catalog no : M36832
cas no: 2226238-09-9
Recifercept (TA-46) is a recombinant human soluble fibroblast growth factor receptor 3, a decoy protein that competes for the ligand of mutant FGFR3.
-
Vofatamab
catalog no : M36756
cas no: 1312305-12-6
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
-
Bemarituzumab
catalog no : M36659
cas no: 1952272-74-0
Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.
-
Aprutumab
catalog no : M36658
cas no: 1634620-63-5
Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
-
FGFR2-IN-2
catalog no : M35560
cas no: 2677709-81-6
FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.